NASDAQ:PMN Promis Neurosciences Q4 2024 Earnings Report $12.60 -0.30 (-2.33%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Promis Neurosciences EPS ResultsActual EPS-$0.50Consensus EPS -$3.50Beat/MissBeat by +$3.00One Year Ago EPSN/APromis Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APromis Neurosciences Announcement DetailsQuarterQ4 2024Date3/31/2025TimeBefore Market OpensConference Call DateMonday, March 31, 2025Conference Call Time7:00AM ETUpcoming EarningsPromis Neurosciences' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Promis Neurosciences Earnings HeadlinesProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberSeptember 1, 2026 | globenewswire.comPromis Neurosciences (NASDAQ:PMN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 1, 2026 | americanbankingnews.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 6 at 1:00 AM | Traders Agency (Ad)Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)August 22, 2026 | theglobeandmail.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 13, 2026 | finanznachrichten.deProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 13, 2026 | globenewswire.comSee More Promis Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email. Email Address About Promis NeurosciencesPromis Neurosciences (NASDAQ:PMN), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis. Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration. Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies. The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.View Promis Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround StorySnowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityGitLab’s AI Tools Are Starting to Turn Developer Demand Into Real RevenueMerchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
